ClinicalTrials.gg
CompletedNCT06644378Updated Jan 22, 2025

A Study of [14C]-LY3866288 in Healthy Participants

A Phase 1 interventional study of [14C]-LY3866288 and LY3866288 in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-22.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main purpose of this study is to evaluate how much of the study drug (LY3866288), administered as a single dose that has the radioactive substance 14C incorporated into it, passes from blood into urine, feces and expired air in healthy participants. The study will also measure how much of the study drug gets into the bloodstream when taken orally, compared to when injected directly into the vein, how its broken down, and how long it takes the body to get rid of it. The study will also evaluate the safety and tolerability of LY3866288.The study is conducted in two parts. The study is expected to last approximately 68 days.

02

Conditions studied

  • Healthy

Keywords

  • Radioactive
  • ADME
  • Disposition
  • Bioavailability
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants who are overtly healthy determined by medical history, physical examination, 12-lead ECGs, vital signs measurements, and clinical laboratory evaluations at screening and/or check-in by the investigator
  • Have between 18.0 and 32.0 kg/m\^2 (kilograms per meter squared)
  • Male participants who are infertile via bilateral orchiectomy or vasectomy
  • Female participants (non- only for Part A) who follow standard methods

Exclusion criteria

Exclusion Criteria:

  • Female participants who are lactating or pregnant
  • Have history of alcohol and/or drug abuse within 2 years prior to screening
  • Have history or presence of any diseases or conditions of clinical significance by the Investigator (or designee) and/or Sponsor
  • Have history of significant , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the investigator
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Part A: [14C]-LY3866288

    Single dose of \[¹⁴C\]-LY3866288 administered orally.

    Drug: [14C]-LY3866288

  • Experimental
    Part B: LY3866288 + [14C]-LY3866288

    Single dose of LY3866288 administered orally followed by a single dose of \[¹⁴C\]-LY3866288 administered intravenously (IV).

    Drug: LY3866288 · Drug: [14C]-LY3866288

Interventions

06

What researchers measure

Primary outcomes

  1. Part A, Fraction of [14C]-LY3866288 Dose Excreted in Urine (Feur) Expressed as a Percentage of the Total Radioactive Dose Administered

    Time frame: Predose up to Day 21 postdose

  2. Part A, Fraction of Dose [14C]-LY3866288 Excreted in Feces Expressed as a Percentage of the Total Radioactive Dose Administered

    Time frame: Predose up to Day 21 postdose

  3. Part B, Absolute Bioavailability (Fabs) of LY3866288

    Time frame: Predose up to Day 9 postdose

Secondary outcomes

  1. Part A: Pharmacokinetics (PK): Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) of LY3866288 in Plasma Following a Single Oral Dose of [14C]-LY3866288

    Time frame: Predose up to Day 7 postdose

  2. Part A: Pharmacokinetics (PK): Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) of Total Radioactivity in Plasma and Whole Blood Following a Single Oral Dose of [14C]-LY3866288

    Time frame: Predose up to Day 21 postdose

  3. Part A: PK: Maximum Observed Plasma Concentration (Cmax) of LY3866288 in Plasma Following a Single Oral Dose of [14C]-LY3866288

    Time frame: Predose up to Day 7 postdose

  4. Part A: PK: Maximum Observed Plasma Concentration (Cmax) of Total Radioactivity in Plasma and Whole Blood Following a Single Oral Dose of [14C]-LY3866288

    Time frame: Predose up to Day 21 postdose

  5. Part A: PK: Ratio of AUC0-inf of Plasma LY3866288 to AUC0-inf of Plasma Total Radioactivity

    Time frame: Predose up to Day 21 postdose

  6. Part A: PK: Ratio of AUC0-inf of Whole Blood Total Radioactivity to AUC0-inf of Plasma Total Radioactivity

    Time frame: Predose up to Day 21 postdose

  7. Part B: PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) of LY3866288 in Plasma

    Time frame: Predose up to Day 9 postdose

  8. Part B: PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) of [14C]-LY3866288 in Plasma

    Time frame: Predose up to Day 9 postdose

  9. Part B: PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) of Total Radioactivity in Plasma

    Time frame: Predose up to Day 9 postdose

  10. Part B: PK: Maximum Observed Plasma Concentration (Cmax) of LY3866288 in Plasma

    Time frame: Predose up to Day 9 postdose

  11. Part B: PK: Maximum Observed Plasma Concentration (Cmax) of [14C]-LY3866288 in Plasma

    Time frame: Predose up to Day 9 postdose

  12. Part B: PK: Maximum Observed Plasma Concentration (Cmax) of Total Radioactivity in Plasma

    Time frame: Predose up to Day 9 postdose

07

Study locations

1 site
  • Fortrea Clinical Research Unit
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Jan 2025, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2024
First posted
Oct 16, 2024
StartActual
Oct 28, 2024
Primary completionActual
Jan 3, 2025
CompletionActual
Jan 3, 2025
Last update
Jan 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06644378
Responsible party
Sponsor
First posted
Oct 16, 2024
Start date
Oct 28, 2024
Primary completion
Jan 3, 2025
Completion
Jan 3, 2025
Last update
Jan 22, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vepugratinib

Start the discussion